Vertex Pharmaceuticals Incorporated (VRTX)

NMS – Цена в реальном времени. Валюта: USD

526.63

-3.02 (-0.57%)

Рынок открыт: Aug 12, 2026, 1:09 PM EDT

529.99

+0.34 (0.06%)

Предыдущая сессия: Aug 11, 2026, 7:55 PM EDT

11.08.2026

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

10.08.2026

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.

07.08.2026

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals could face competition in its most important market by far. The company is preparing for that by diversifying its lineup and pipeline.

04.08.2026

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

Its sales rose at a double-digit rate; net profit growth was more modest. There's another development with the company more worth monitoring, however.

04.08.2026

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.

04.08.2026

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.

04.08.2026

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise growth platform. 2Q26 revenue rose 12% to $3.33 billion, with strong CF performance and early scaling of Casgevy and Journvax supporting raised FY26 guidance to $13.1–$13.2 billion. VRTX is aggressively reinvesting in pipeline and commercial launches, leveraging a $13.6 billion cash position and diversifying with the Crinetics acquisition.

Видео

No Data

There is no data to display

Пресс-релизы

03.08.2026

Vertex Reports Second Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pilla.

Vertex Pharmaceuticals Incorporated (VRTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vertex Pharmaceuticals Incorporated (VRTX)

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Видео

No Data

Пресс-релизы

Vertex Reports Second Quarter 2026 Financial Results

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Видео

No Data

Пресс-релизы

Vertex Reports Second Quarter 2026 Financial Results

Search stocks

Vertex Pharmaceuticals Incorporated (VRTX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vertex Pharmaceuticals Incorporated (VRTX)

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Видео

No Data

Пресс-релизы

Vertex Reports Second Quarter 2026 Financial Results

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story

Видео

No Data

Пресс-релизы

Vertex Reports Second Quarter 2026 Financial Results